Home › Research › Treatments
Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study
Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M, Takahashi K, Mori N. Alzheimer's & Dementia, 2024-10-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction We evaluated the efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia (AAD) in Japanese patients. Methods This was a phase 2/3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Patients with AAD were randomized to receive brexpiprazole 1 mg/day or 2 mg/day, or placebo (3:4:4) for 10 weeks. Results For the primary endpoint (change in Cohen-Mansfield Agitation Inventory [CMAI] total score from baseline to Week 10), both brexpiprazole 1 mg and 2 mg groups demonstrated statistically significant improvement versus placebo (2 mg: least squares [LS] mean difference -7.2 [95% confidence interval (CI): -10.0 to -4.3], p-value Discussion Brexpiprazole 1 mg/day and 2 mg/day for 10 weeks was efficacious and well tolerated. Highlights Brexpiprazole treatment for 10 weeks improved agitation in Alzheimer's dementia. The efficacy of brexpiprazole 1 mg/day has been confirmed for the first time. The incidence of adverse events was higher compared to the previous studies. Both brexpiprazole 1 mg/day and 2 mg/day were generally well tolerated.
What this study adds
Evidence grade: Moderate
In this 10-week trial, both brexpiprazole 1 mg and 2 mg significantly improved agitation in Alzheimer's dementia compared with placebo. Reported effect size: CMAI change vs placebo: -7.2 (95% CI -10.0 to -4.3) at 2 mg; -3.7 (95% CI -6.8 to -0.7) at 1 mg.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nakamura, Y., Adachi, J., Hirota, N., Iba, K., Shimizu, K., Nakai, M., et al. (2024). Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14282
Vancouver
Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M, et al. Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14282. PMID: 39369280.
BibTeX
@article{nakamura2024-39369280,
author = {Nakamura, Y. and Adachi, J. and Hirota, N. and Iba, K. and Shimizu, K. and Nakai, M. and Takahashi, K. and Mori, N.},
title = {{Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study}},
journal = {Alzheimer's \& Dementia},
year = {2024},
doi = {10.1002/alz.14282},
pmid = {39369280},
url = {https://doi.org/10.1002/alz.14282}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results For the primary endpoint (change in Cohen-Mansfield Agitation Inventory [CMAI] total score from baseline to Week 10), both brexpiprazole 1 mg and 2 mg groups demonstrated statistically significant improvement versus placebo (2 mg: least squares [LS] mean difference -7.2 [95% confidence interval (CI): -10.0 to -4.3], p-value < 0.0001, 1 mg: LS mean difference -3.7 [95% CI: -6.8 to -0.7], p-value = 0.0175).
- The incidence of adverse events was higher compared to the previous studies.
Why it matters
In this 10-week trial, both brexpiprazole 1 mg and 2 mg significantly improved agitation in Alzheimer's dementia compared with placebo. The incidence of adverse events was higher than in previous studies, though both doses were generally well tolerated.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designphase-3-trial
- Effect sizeCMAI change vs placebo: -7.2 (95% CI -10.0 to -4.3) at 2 mg; -3.7 (95% CI -6.8 to -0.7) at 1 mg
- Evidence strengthModerate
Limitations
Japanese population only; 10-week duration cannot assess long-term safety including the class-wide mortality warning for antipsychotics in dementia; industry-sponsored; sample size not stated in the abstract.
How this study scored 61/100
Published in a leading specialty journal, and it is a large phase 3 trial. Scored zero for sample size and studied in people because the record does not state it. We have no data on free to read, so that was left out: it earned 60 of the 98 points we could judge it on, which is 61 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 3 / 7 | Cited 34 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 4 / 6 | Cited 9.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 34 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Naoki Mori: h-index 49 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Kagawa University: institution h-index 269 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39369280) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 60 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 60 of the 98 points we could judge it on is 61 out of 100. |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.